(Total Views: 585)
Posted On: 11/22/2025 5:21:42 AM
Post# of 158791
https://seekingalpha.com/news/4525053-merck-k...der-cancer
Excerpt: "The approvals were based on the companies’ KEYNOTE-905 trial, in which Keytruda plus Padcev as perioperative treatment led to statistically significant improvements in event-free survival and overall survival compared to surgery in MIBC patients for whom cisplatin is not indicated."
The data, from the phase 3 KEYNOTE-905 trial (NCT03924895), were presented to rounds of applause during a session at the 2025 European Society for Medical Oncology Congress in Berlin, Germany.
Formulations are coming.
Excerpt: "The approvals were based on the companies’ KEYNOTE-905 trial, in which Keytruda plus Padcev as perioperative treatment led to statistically significant improvements in event-free survival and overall survival compared to surgery in MIBC patients for whom cisplatin is not indicated."
The data, from the phase 3 KEYNOTE-905 trial (NCT03924895), were presented to rounds of applause during a session at the 2025 European Society for Medical Oncology Congress in Berlin, Germany.
Formulations are coming.
(3)
(0)
